Holders over time
- BRVE
- TMO
| Quarter | BRVE | TMO |
|---|---|---|
| Q4 2020 | none listed holders, n.a. | 33 holders, $39.2bn |
| Q1 2021 | none listed holders, n.a. | 35 holders, $36.5bn |
| Q2 2021 | none listed holders, n.a. | 33 holders, $38.3bn |
| Q3 2021 | none listed holders, n.a. | 32 holders, $42.6bn |
| Q4 2021 | none listed holders, n.a. | 38 holders, $50.1bn |
| Q1 2022 | none listed holders, n.a. | 32 holders, $43.2bn |
| Q2 2022 | none listed holders, n.a. | 33 holders, $38.9bn |
| Q3 2022 | none listed holders, n.a. | 26 holders, $34.3bn |
| Q4 2022 | none listed holders, n.a. | 29 holders, $37.0bn |
| Q1 2023 | none listed holders, n.a. | 35 holders, $37.1bn |
| Q2 2023 | none listed holders, n.a. | 39 holders, $33.5bn |
| Q3 2023 | none listed holders, n.a. | 39 holders, $32.6bn |
| Q4 2023 | none listed holders, n.a. | 41 holders, $32.7bn |
| Q1 2024 | none listed holders, n.a. | 30 holders, $34.1bn |
| Q2 2024 | none listed holders, n.a. | 38 holders, $30.6bn |
| Q3 2024 | none listed holders, n.a. | 30 holders, $33.8bn |
| Q4 2024 | none listed holders, n.a. | 36 holders, $27.6bn |
| Q1 2025 | none listed holders, n.a. | 31 holders, $24.2bn |
| Q2 2025 | none listed holders, n.a. | 39 holders, $18.8bn |
| Q3 2025 | none listed holders, n.a. | 32 holders, $21.9bn |
| Q4 2025 | none listed holders, n.a. | 32 holders, $29.9bn |
| Q1 2026 | none listed holders, n.a. | 34 holders, $24.4bn |
| Q2 2026 | none listed holders, n.a. | 36 holders, $26.4bn |
| Q3 2026 | 3 holders, $28m | 35 holders, $40.3bn |
Braveheart Bio Inc
- Holders
- 0
- Reported value
- $0
- Buyers
- n.a.
- Sellers
- n.a.
No cross-section for this quarter.
Thermo Fisher Scientific Inc
- Holders
- 41
- Reported value
- $32.7bn
- Buyers
- 19
- Sellers
- 23
Breadth -4 among 93 comparable managers.
Who holds both, Q4 2023
Both (0)
No tracked manager lists every one of them.
Only BRVE (0)
None.
Only TMO (41)
Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, and 16 more
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.